Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Clinical trial NCT00496366 · TERMINATED
Trial details
- NCT number
- NCT00496366
- Sponsor
- Rutgers, The State University of New Jersey
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2007-07-23
- Primary completion
- 2009-12-31
- Enrollment
- 11
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.